Recruiting
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
NCT07218315· M.D. Anderson Cancer Center· Source
Contact: Ralph Tufano, MD
Recruiting
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· Phase 3· National Cancer Institute (NCI)· Source
Contact: Toni P. Kilts (principal investigator)
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· National Cancer Institute (NCI)· Source
Contact: Toni P. Kilts (principal investigator)
Recruiting
BoxX-NoAF Clinical Trial
NCT06989775· AtriCure, Inc.· Source
Contact: Marisa Mamazza
Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
NCT07069738· Boston Scientific Corporation· Source
Contact: Antonio Moretta, Dr.
Active, not recruiting
SPHERE Per-AF Post-Approval Study
NCT06858306· Medtronic Cardiac Ablation Solutions· Source
Active, not recruiting
Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System
NCT07287176· Pulse Biosciences, Inc.· Source
Recruiting
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244· Phase 3· Pharmazz, Inc.· Source
Contact: Dr. Mauricio Concha
Recruiting
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
NCT07001800· Phase 2/3· Kardigan, Inc.· Source
Recruiting
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NCT06532279· Phase 2· NRG Oncology· Source
Contact: Kunal Saigal (principal investigator)
Active, not recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· Phase 3· Genmab· Source
Recruiting
The PERSEVERE Study
NCT06588634· Inari Medical· Source
Contact: Clinton Wrigley, MD
Enrolling by invitation
Xeltis Hemodialysis Access Graft (aXess) US Study
NCT06494631· Xeltis· Source
Active, not recruiting
SIMPLAAFY Clinical Trial
NCT06521463· Boston Scientific Corporation· Source
Recruiting
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
NCT05611242· Phase 3· Mercy Health Ohio· Source
Contact: Alexandria Serafine
Enrolling by invitation
A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF
NCT06335082· Heart Rhythm Clinical and Research Solutions, LLC· Source
Active, not recruiting
Real-world Safety and Effectiveness Registry of Catheter Ablation of Paroxysmal Atrial Fibrillation as Initial Control Therapy With the Thermocool SmartTouch SF Catheter (A Sub-study of REAL AF Registry)
NCT07092774· Heart Rhythm Clinical and Research Solutions, LLC· Source
Active, not recruiting
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
NCT06096337· Boston Scientific Corporation· Source
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638· Orchestra BioMed, Inc· Source
Contact: Steven J. Evans, MD
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Pavankumar Tandra (principal investigator)
Recruiting
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312· Phase 1/2· Perspective Therapeutics· Source
Contact: Michelle Perkalis
Active, not recruiting
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT05538897· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304· AtriCure, Inc.· Source
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917· Inari Medical· Source
Contact: Juan C Camacho-Vasquez, MD
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347· Medtronic Cardiovascular· Source
Contact: Jason Wagner, MD (principal investigator)
Recruiting
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT05640999· Phase 2· Canadian Cancer Trials Group· Source
Contact: Beverly Long
Active, not recruiting
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Inappropriate Sinus Tachycardia Registry
NCT05107635· AtriCure, Inc.· Source
Contact: Alexandra Gardner
Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673· NRG Oncology· Source
Contact: Kenneth L. Meredith (principal investigator)
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216· Phase 2/3· DiaMedica Therapeutics Inc· Source
Contact: Mauricio Concha, M.D.
Active, not recruiting
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
NCT04671771· W.L.Gore & Associates· Source
Active, not recruiting
The ENCIRCLE Trial
NCT04153292· Edwards Lifesciences· Source
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Source
Contact: Toni P. Kilts (principal investigator)
Active, not recruiting
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04214262· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Amplatzer Amulet LAAO vs. NOAC
NCT04226547· Abbott Medical Devices· Source
Active, not recruiting
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
NCT03348631· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Florida Pancreas Collaborative Next Generation Biobank
NCT03851133· H. Lee Moffitt Cancer Center and Research Institute· Source
Active, not recruiting
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis
NCT03517436· Edwards Lifesciences· Source
Recruiting
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
NCT04088071· Heart Rhythm Clinical and Research Solutions, LLC· Source
Contact: Colleen Linder
Active, not recruiting
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System
NCT02514525· Pentax Medical· Source